PROBUCOL PROTECTS LIPOPROTEIN(A) AGAINST OXIDATIVE MODIFICATION

被引：22

作者：

NARUSZEWICZ, M ^{[1
]}

SELINGER, E ^{[1
]}

DUFOUR, R ^{[1
]}

DAVIGNON, J ^{[1
]}

机构：

[1] HOP HOTEL DIEU,MONTREAL H2W 1T8,QUEBEC,CANADA

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 1992年 / 41卷 / 11期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1016/0026-0495(92)90013-Z

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Probucol, which decreases cholesterol levels and has antioxidant properties, was administered orally to patients with familial combined hyperlipidemia and high plasma lipoprotein(a) [Lp(a)] levels. The drug had no effect on Lp(a) concentrations after 4 weeks, but was found to be distributed in both Lp(a) and low-density lipoprotein (LDL). Before treatment, in each case LDL and Lp(a) isolated from the same individual were readily oxidized by copper, resulting in increased electrophoretic mobility and enhanced uptake and degradation by macrophages of both lipoproteins. After probucol treatment, both lipoproteins acquired resistance to in vitro oxidation by copper. Furthermore, probucol prevented their enhanced uptake and degradation by the macrophages. It is surmised that oxidized Lp(a) may carry an atherogenic potential that could be opposed by probucol administration. © 1992.

引用

页码：1225 / 1228

页数：4

共 25 条

[1] REDUCTION OF LECITHIN-CHOLESTEROL ACYLTRANSFERASE, APOLIPOPROTEIN D AND THE LP(A) LIPOPROTEIN WITH THE ANABOLIC-STEROID STANOZOLOL [J].